{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:46:33Z","timestamp":1792449993104,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10585-024-10327-w","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T04:08:26Z","timestamp":1735531706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study"],"prefix":"10.1007","volume":"42","author":[{"given":"Alessandro","family":"Rizzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Sabino Marques","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mollica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oronzo","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Monica","family":"Sciacovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"10327_CR1","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Frontera OA, Melichar B, Choueiri TK et al (2018) Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med","DOI":"10.1056\/NEJMoa1712126"},{"issue":"5","key":"10327_CR2","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.euo.2021.03.001","volume":"4","author":"F Quhal","year":"2021","unstructured":"Quhal F, Mori K, Bruchbacher A, Resch I, Mostafaei H, Pradere B, Schuettfort VM, Laukhtina E, Egawa S, Fajkovic H, Remzi M, Shariat SF, Schmidinger M (2021) First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network Meta-analysis. Eur Urol Oncol 4(5):755\u2013765. https:\/\/doi.org\/10.1016\/j.euo.2021.03.001Epub 2021 Mar 20. PMID: 33757737","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10327_CR3","doi-asserted-by":"publisher","first-page":"e2021869","DOI":"10.1001\/jamanetworkopen.2020.21869","volume":"4","author":"S Dudani","year":"2021","unstructured":"Dudani S, de Velasco G, Wells JC, Gan CL, Donskov F, Porta C, Fraccon A, Pasini F, Lee JL, Hansen A, Bjarnason GA, Beuselinck B, Pal SK, Yuasa T, Kroeger N, Kanesvaran R, Reaume MN, Canil C, Choueiri TK, Heng DYC (2021) Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association with Survival. JAMA Netw Open 4(1):e2021869. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.21869. PMID: 33475752; PMCID: PMC7821027","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10327_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.clgc.2020.06.003","volume":"19","author":"F Massari","year":"2021","unstructured":"Massari F, Di Nunno V, Guida A, Costa Silva CA, Derosa L, Mollica V, Colomba E, Brandi G, Albiges L (2021) Addition of primary metastatic site on bone, brain, and liver to IMDC Criteria in patients with metastatic renal cell carcinoma: a validation study. Clin Genitourin Cancer 19(1):32\u201340 Epub 2020 Jun 27. PMID: 32694008","journal-title":"Clin Genitourin Cancer"},{"key":"10327_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.11604\/pamj.2022.42.26.33578","volume":"42","author":"A Singla","year":"2022","unstructured":"Singla A, Sharma U, Makkar A, Masood PF, Goel HK, Sood R, Ahuja A, Singh R (2022) Rare metastatic sites of renal cell carcinoma: a case series. Pan Afr Med J 42:26. https:\/\/doi.org\/10.11604\/pamj.2022.42.26.33578. PMID: 35910051; PMCID: PMC9288148","journal-title":"Pan Afr Med J"},{"issue":"4","key":"10327_CR6","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/annonc\/mdr362","volume":"23","author":"M Bianchi","year":"2012","unstructured":"Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23(4):973\u2013980. https:\/\/doi.org\/10.1093\/annonc\/mdr362Epub 2011 Sep 2. PMID: 21890909","journal-title":"Ann Oncol"},{"issue":"3","key":"10327_CR7","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.3390\/tomography8030110","volume":"8","author":"A Jajodia","year":"2022","unstructured":"Jajodia A, Goel V, Patnaik N, Pasricha S, Gupta G, Batra U, Talwar V (2022) Analysis of spatial heterogeneity of responses in metastatic sites in Renal Cell Carcinoma patients treated with Nivolumab. Tomography 8(3):1363\u20131373. https:\/\/doi.org\/10.3390\/tomography8030110. PMID: 35645396; PMCID: PMC9149819","journal-title":"Tomography"},{"key":"10327_CR8","doi-asserted-by":"publisher","unstructured":"Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L, Peters S, Arvold ND, Harsh GR, Steeg PS, Chang SD (2019) Brain metastases. Nat Rev Dis Primers. 5(1):5. https:\/\/doi.org\/10.1038\/s41572-018-0055-y. PMID: 30655533","DOI":"10.1038\/s41572-018-0055-y"},{"key":"10327_CR9","doi-asserted-by":"publisher","unstructured":"Franzese C, Franceschini D, Di Brina L, D\u2019Agostino GR, Navarria P, Comito T, Mancosu P, Tomatis S, Scorsetti M (2019) Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma. J Urol. 201(1):70\u201376. https:\/\/doi.org\/10.1016\/j.juro.2018.08.049. PMID: 30179619","DOI":"10.1016\/j.juro.2018.08.049"},{"key":"10327_CR10","doi-asserted-by":"publisher","first-page":"175883592090750","DOI":"10.1177\/1758835920907504","volume":"12","author":"E Rassy","year":"2020","unstructured":"Rassy E, Flippot R, Albiges L (2020) Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Ther Adv Med Oncol 12:1758835920907504","journal-title":"Ther Adv Med Oncol"},{"key":"10327_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2019.05.022","volume":"76","author":"L Albiges","year":"2019","unstructured":"Albiges L, Powles T, Staehler M et al (2019) Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint inhibition is the New Backbone in First-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol 76:151\u2013156","journal-title":"Eur Urol"},{"key":"10327_CR12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.annonc.2020.11.016","volume":"32","author":"T Powles","year":"2021","unstructured":"Powles T, ESMO Guidelines Committee (2021) Electronic address: clinicalguidelines@esmo.org. Recent eUpdate to the ESMO Clinical Practice guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: renal cell carcinoma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 32:422\u2013423","journal-title":"Ann Oncol"},{"key":"10327_CR13","doi-asserted-by":"publisher","first-page":"7321","DOI":"10.2147\/CMAR.S216605","volume":"12","author":"V Chau","year":"2020","unstructured":"Chau V, Bilusic M (2020) Pembrolizumab in Combination with Axitinib as First-Line treatment for patients with renal cell carcinoma (RCC): evidence to date. Cancer Manag Res 12:7321\u20137330","journal-title":"Cancer Manag Res"},{"key":"10327_CR14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/MOU.0000000000000874","volume":"31","author":"M Schmidinger","year":"2021","unstructured":"Schmidinger M, Resch I, Fajkovic H, Remzi M, Shariat SF, Bedke J (2021) Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma? Curr Opin Urol 31:270\u2013275","journal-title":"Curr Opin Urol"},{"issue":"14","key":"10327_CR15","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Gr\u00fcnwald V, Hutson TE, Kopyltsov E, M\u00e9ndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK, CLEAR Trial Investigators (2021) Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med 384(14):1289\u20131300. https:\/\/doi.org\/10.1056\/NEJMoa2035716Epub 2021 Feb 13. PMID: 33616314","journal-title":"N Engl J Med"},{"key":"10327_CR16","doi-asserted-by":"publisher","unstructured":"Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Su\u00e1rez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TK (2022) Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol.;23(7):888\u2013898. https:\/\/doi.org\/10.1016\/S1470-2045(22)00290-X. Epub 2022 Jun 7. Erratum in: Lancet Oncol. 2022;23(7):e319. https:\/\/doi.org\/10.1016\/S1470-2045(22)00346-110.1016\/S1470-2045(22)00346-1. Erratum in: Lancet Oncol. 2022;23(9):e404. https:\/\/doi.org\/10.1016\/S1470-2045(22)00511-3. PMID: 35688173; PMCID: PMC10305087","DOI":"10.1016\/S1470-2045(22)00290-X 10.1016\/S1470-2045(22)00346-1 10.1016\/S1470-2045(22)00511-3"},{"issue":"6","key":"10327_CR17","doi-asserted-by":"publisher","first-page":"e001079","DOI":"10.1136\/esmoopen-2020-001079","volume":"5","author":"L Albiges","year":"2020","unstructured":"Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barth\u00e9l\u00e9my P, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Grimm MO, Tomita Y, Castellano D, Rini BI, Choueiri TK, Saggi SS, McHenry MB, Motzer RJ (2020) Nivolumab plus Ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 5(6):e001079. https:\/\/doi.org\/10.1136\/esmoopen-2020-001079. PMID: 33246931; PMCID: PMC7703447","journal-title":"ESMO Open"},{"issue":"3","key":"10327_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41585-022-00676-0","volume":"20","author":"M Rosellini","year":"2023","unstructured":"Rosellini M, Marchetti A, Mollica V, Rizzo A, Santoni M, Massari F (2023) Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat Rev Urol 20(3):133\u2013157. https:\/\/doi.org\/10.1038\/s41585-022-00676-0Epub 2022 Nov 21. PMID: 36414800","journal-title":"Nat Rev Urol"},{"key":"10327_CR19","doi-asserted-by":"publisher","unstructured":"Su\u00e1rez C, Campayo M, Bast\u00fas R, Castillo S, Etxanitz O, Guix M, Sala N, Gallardo E (2018) Prognostic and Predictive Factors for Renal Cell Carcinoma. Target Oncol.;13(3):309\u2013331. https:\/\/doi.org\/10.1007\/s11523-018-0557-2. PMID: 29569164","DOI":"10.1007\/s11523-018-0557-2"},{"key":"10327_CR20","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535","journal-title":"BMJ"},{"key":"10327_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane hand-book for systematic reviews of interventions","author":"JPT Higgins","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J et al (2019) Cochrane hand-book for systematic reviews of interventions, 2nd edn. Wiley, Chichester (UK)","edition":"2"},{"key":"10327_CR22","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, Cochrane Bias Methods Group; Cochrane Statistical Methods Group et al (2011) The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"key":"10327_CR23","doi-asserted-by":"publisher","first-page":"17822","DOI":"10.1038\/s41598-021-97365-6","volume":"11","author":"H Wei","year":"2021","unstructured":"Wei H, Miao J, Cui J et al (2021) The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: analysis based on the SEER database. Sci Rep 11:17822. https:\/\/doi.org\/10.1038\/s41598-021-97365-6","journal-title":"Sci Rep"},{"issue":"1","key":"10327_CR24","doi-asserted-by":"publisher","first-page":"e2021869","DOI":"10.1001\/jamanetworkopen.2020.21869","volume":"4","author":"S Dudani","year":"2021","unstructured":"Dudani S, de Velasco G, Wells JC et al (2021) Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association with Survival. JAMA Netw Open 4(1):e2021869. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.21869","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10327_CR25","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.rmed.2010.04.026","volume":"104","author":"T Kumar","year":"2010","unstructured":"Kumar T, Patel N, Talwar A (2010) Spontaneous regression of thoracic malignancies. Respir Med 104(10):1543\u20131550. https:\/\/doi.org\/10.1016\/j.rmed.2010.04.026Epub 2010 May 23. PMID: 20580882","journal-title":"Respir Med"},{"key":"10327_CR26","doi-asserted-by":"publisher","unstructured":"Zekri J, Ahmed N, Coleman RE, Hancock BW (2001) The skeletal metastatic complications of renal cell carcinoma. Int J Oncol.;19(2):379\u2013\u200982. https:\/\/doi.org\/10.3892\/ijo.19.2.379. PMID: 11445855","DOI":"10.3892\/ijo.19.2.379"},{"key":"10327_CR27","doi-asserted-by":"publisher","unstructured":"Escudier B, Powles T, Motzer RJ, Olencki T, Ar\u00e9n Frontera O, Oudard S, Rolland F,Tomczak P, Castellano D, Appleman LJ, Drabkin H, Vaena D, Milwee S, Youkstetter J,Lougheed JC, Bracarda S, Choueiri TK. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. J Clin Oncol. 2018;36(8):765\u2013772. https:\/\/doi.org\/10.1200\/JCO.2017.74.7352. Epub 2018 Jan 8. PMID: 29309249; PMCID: PMC6804840.","DOI":"10.1200\/JCO.2017.74.7352"},{"issue":"20","key":"10327_CR28","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.3390\/cancers15205095","volume":"15","author":"K Mazurec","year":"2023","unstructured":"Mazurec K, Trzeszcz M, Mazurec M, Streb J, Halon A, Jach R (2023) Triage strategies for Non-16\/Non-18 HPV-Positive women in primary HPV-Based cervical Cancer screening: p16\/Ki67 dual stain vs. Cytol Cancers (Basel) 15(20):5095. https:\/\/doi.org\/10.3390\/cancers15205095. PMID: 37894462; PMCID: PMC10605570","journal-title":"Cytol Cancers (Basel)"},{"key":"10327_CR29","doi-asserted-by":"publisher","unstructured":"Lau G, Abou-Alfa GK, Cheng AL, Sukeepaisarnjaroen W, Dao TV, Kang YK, Thungappa SC, Kudo M, Sangro B, Kelley RK, Furuse J, Park JW, Sunpaweravong P, Fasolo A, Yau T, Kawaoka T, Azevedo S, Reig M, Assenat E, Yarchoan M, He AR, Makowsky M, Gupta C, Negro A, Chan SL Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. J Hepatol 2024 Jul 30:S0168-8278(24)02424-3. https:\/\/doi.org\/10.1016\/j.jhep.2024.07.017. Epub ahead of print. PMID: 39089633.","DOI":"10.1016\/j.jhep.2024.07.017"},{"issue":"19","key":"10327_CR30","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","volume":"388","author":"TK Choueiri","year":"2023","unstructured":"Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, Schutz FA, Heng DYC, Wang F, Mataveli F, Chang YL, van Kooten Losio M, Suarez C, Motzer RJ (2023) COSMIC-313 investigators. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. N Engl J Med 388(19):1767\u20131778. https:\/\/doi.org\/10.1056\/NEJMoa2212851. PMID: 37163623; PMCID: PMC10257898","journal-title":"N Engl J Med"},{"issue":"1","key":"10327_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12874-018-0618-3","volume":"19","author":"SE Seide","year":"2019","unstructured":"Seide SE, R\u00f6ver C, Friede T (2019) Likelihood-based random-effects meta-analysis with few studies: empirical and simulation studies. BMC Med Res Methodol 19(1):16. https:\/\/doi.org\/10.1186\/s12874-018-0618-3. PMID: 30634920; PMCID: PMC6330405","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"10327_CR32","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/j.clgc.2019.08.007","volume":"18","author":"V Di Nunno","year":"2020","unstructured":"Di Nunno V, Mollica V, Schiavina R, Nobili E, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F (2020) Improving IMDC Prognostic Prediction through evaluation of initial site of metastasis in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 18(2):e83\u2013e90 Epub 2019 Aug 20. PMID: 31753738","journal-title":"Clin Genitourin Cancer"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-024-10327-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-024-10327-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-024-10327-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T08:02:06Z","timestamp":1738742526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-024-10327-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10327"],"URL":"https:\/\/doi.org\/10.1007\/s10585-024-10327-w","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"10 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}